Artivion, Inc. (AORT)

Artivion's stock has fluctuated between $22.19 and $47.63 over the past 52 weeks, with a 26.2% increase over the last year. Strong Q2 earnings led to analysts raising price targets. Marshall S. Stanton sold 18,200 shares. Q3 earnings reported an EPS of $0.16, beating estimates. Positive clinical data presentations were followed by modest gains. The average analyst target price suggests room for growth, with strong market confidence. Several executives and directors engaged in stock sales in November and December 2025. The company faced costs from a cybersecurity incident, which presented some challenges.

Artivion experiences demand seasonality, with Q1 typically being the worst free cash flow quarter due to annual bonuses, sales meetings, and industry meetings. The company's xenograft pulmonary valves face consistent demand that outstrips supply every quarter. A backlog of tissue products due to extended lead times impacted by a cyber incident was expected to be resolved by the end of the year.

Artivion, Inc. is a medical device company specializing in medical devices and implantable human tissues, primarily for cardiac and vascular surgical procedures. The company operates through Medical Devices and Preservation Services segments, offering products like aortic stent grafts, surgical sealants, mechanical heart valves, and preservation services for cardiac and vascular tissues. Artivion also sells surgical patches and hemostatic powder. Founded in 1984 and headquartered in Kennesaw, Georgia, it operates within the healthcare sector, specifically the medical devices industry.

Artivion operates globally with manufacturing centers in Kennesaw, Georgia; Austin, Texas; and Hechingen, Germany. It markets products directly in the US and Canada and uses distributors and subsidiaries in EMEA, APAC, and LATAM, reaching over 100 countries. The company has a direct sales force in key European countries and has demonstrated strong performance in emerging markets.

Artivion's brand reputation is largely positive due to strong financial performance, positive analyst sentiment, successful product launches, and positive clinical trial data. The company has demonstrated strong financial performance with a notable increase in adjusted EBITDA margin and robust demand for its aortic-centric medical devices. Artivion has received a consensus rating of "Moderate Buy" from analysts, indicating strong market confidence. Consistent positive clinical trial presentations for its aortic portfolio have strengthened evidence for its products. A cybersecurity incident led to operational challenges and costs, potentially affecting the company's reputation.

Artivion's ownership is a mix of institutional, retail, and individual investors. Approximately 51.52% is owned by Institutional Investors, 4.52% by Insiders, and 43.96% by Public Companies and Individual Investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Fmr Llc.